207 related articles for article (PubMed ID: 11740737)
21. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC
J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336
[TBL] [Abstract][Full Text] [Related]
22. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
[TBL] [Abstract][Full Text] [Related]
23. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
Shibata R; Igarashi T; Haigwood N; Buckler-White A; Ogert R; Ross W; Willey R; Cho MW; Martin MA
Nat Med; 1999 Feb; 5(2):204-10. PubMed ID: 9930869
[TBL] [Abstract][Full Text] [Related]
24. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
[TBL] [Abstract][Full Text] [Related]
25. Humoral immunity to HIV, SIV, and SHIV.
Haigwood NL; Zolla-Pazner S
AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
[No Abstract] [Full Text] [Related]
26. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model.
Nehete PN; Nehete BP; Manuri P; Hill L; Palmer JL; Sastry KJ
Vaccine; 2005 Mar; 23(17-18):2154-9. PubMed ID: 15755586
[TBL] [Abstract][Full Text] [Related]
27. Induction of immune response in macaque monkeys infected with simian-human immunodeficiency virus having the TNF-alpha gene at an early stage of infection.
Shimizu Y; Miyazaki Y; Ibuki K; Suzuki H; Kaneyasu K; Goto Y; Hayami M; Miura T; Haga T
Virology; 2005 Dec; 343(2):151-61. PubMed ID: 16169034
[TBL] [Abstract][Full Text] [Related]
28. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.
Cho MW; Kim YB; Lee MK; Gupta KC; Ross W; Plishka R; Buckler-White A; Igarashi T; Theodore T; Byrum R; Kemp C; Montefiori DC; Martin MA
J Virol; 2001 Mar; 75(5):2224-34. PubMed ID: 11160726
[TBL] [Abstract][Full Text] [Related]
29. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL
Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768
[TBL] [Abstract][Full Text] [Related]
30. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA
Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743
[No Abstract] [Full Text] [Related]
31. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
[TBL] [Abstract][Full Text] [Related]
32. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.
Bogers WM; Davis D; Baak I; Kan E; Hofman S; Sun Y; Mortier D; Lian Y; Oostermeijer H; Fagrouch Z; Dubbes R; van der Maas M; Mooij P; Koopman G; Verschoor E; Langedijk JP; Zhao J; Brocca-Cofano E; Robert-Guroff M; Srivastava I; Barnett S; Heeney JL
Virology; 2008 Dec; 382(2):217-25. PubMed ID: 18947849
[TBL] [Abstract][Full Text] [Related]
33. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
[TBL] [Abstract][Full Text] [Related]
34. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.
Silvera P; Richardson MW; Greenhouse J; Yalley-Ogunro J; Shaw N; Mirchandani J; Khalili K; Zagury JF; Lewis MG; Rappaport J
J Virol; 2002 Apr; 76(8):3800-9. PubMed ID: 11907220
[TBL] [Abstract][Full Text] [Related]
35. The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.
Palker TJ; Muir AJ; Spragion DE; Staats HF; Langlois A; Montefiori DC
Virology; 1996 Oct; 224(2):415-26. PubMed ID: 8874502
[TBL] [Abstract][Full Text] [Related]
36. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
Ruprecht RM; Hofmann-Lehmann R; Smith-Franklin BA; Rasmussen RA; Liska V; Vlasak J; Xu W; Baba TW; Chenine AL; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Montefiori DC; McClure HM
Transfus Clin Biol; 2001 Aug; 8(4):350-8. PubMed ID: 11642027
[TBL] [Abstract][Full Text] [Related]
37. Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination.
Wolfs TF; Nara PL; Goudsmit J
Chem Immunol; 1993; 56():1-33. PubMed ID: 8383980
[No Abstract] [Full Text] [Related]
38. Immune responses following simian/human immunodeficiency virus (SHIV) challenge of rhesus macaques after human immunodeficiency virus (HIV)-1 third variable domain (V3) loop-based genetic immunization.
Le Borgne S; Le Grand R; Michel ML; Vaslin B; Boson B; Janvier G; Aubertin AM; Dormont D; Rivière Y
J Med Primatol; 2000 Dec; 29(6):371-86. PubMed ID: 11168828
[TBL] [Abstract][Full Text] [Related]
39. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV
Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X
Viruses; 2018 May; 10(5):. PubMed ID: 29772652
[TBL] [Abstract][Full Text] [Related]
40. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.
Ferrantelli F; Rasmussen RA; Buckley KA; Li PL; Wang T; Montefiori DC; Katinger H; Stiegler G; Anderson DC; McClure HM; Ruprecht RM
J Infect Dis; 2004 Jun; 189(12):2167-73. PubMed ID: 15181562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
